Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Jan;11(1):1–9. doi: 10.1089/dia.2008.0040

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2009, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 1. — (A) Compiled polypeptide patterns of the patients and controls examined. Shown are compiled patterns consisting of all samples from patients with a subsequent CAD event and from controls with no CAD event during the observation period. The molecular mass (0.8–25 kDa, on a logarithmic scale) is plotted against normalized migration time (18–45 min). Signal intensity is encoded by peak height and color. (B) Distribution of the biomarkers for CAD in the same patients as shown in (A), with signal intensity amplified 10-fold in comparison to (A). (C) (Top panels) Compiled polypeptide patterns of all subjects in the study, according to albuminuria (29 normoalbuminuric, six microalbuminuric, and three macroalbuminuric patients). (Bottom panels) Distribution of the 33 biomarkers for chronic renal disease (RD1) in the three groups, with signal intensity amplified 10-fold in comparison to top panels. (D) (Top panels) Compiled polypeptide patterns of all subjects in the study, according to metabolic status (30 with diabetes, eight without diabetes). (Bottom panels) Distribution of the 261 biomarkers for diabetes defined previously in the two groups, with signal intensity amplified 10-fold in comparison to top panels.

FIG. 1. — (A) Compiled polypeptide patterns of the patients and controls examined. Shown are compiled patterns consisting of all samples from patients with a subsequent CAD event and from controls with no CAD event during the observation period. The molecular mass (0.8–25 kDa, on a logarithmic scale) is plotted against normalized migration time (18–45 min). Signal intensity is encoded by peak height and color. (B) Distribution of the biomarkers for CAD in the same patients as shown in (A), with signal intensity amplified 10-fold in comparison to (A). (C) (Top panels) Compiled polypeptide patterns of all subjects in the study, according to albuminuria (29 normoalbuminuric, six microalbuminuric, and three macroalbuminuric patients). (Bottom panels) Distribution of the 33 biomarkers for chronic renal disease (RD1) in the three groups, with signal intensity amplified 10-fold in comparison to top panels. (D) (Top panels) Compiled polypeptide patterns of all subjects in the study, according to metabolic status (30 with diabetes, eight without diabetes). (Bottom panels) Distribution of the 261 biomarkers for diabetes defined previously in the two groups, with signal intensity amplified 10-fold in comparison to top panels.